Beam Therapeutics Inc.NASDAQ: BEAM

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

· Issued by Beam Therapeutics Inc.
Watch Beam Therapeutics explain itBeam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call · Replay · Feb 24

All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to 60%, a decrease in hemoglobin S to